Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$0.69 USD
+0.02 (2.65%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $0.70 +0.01 (0.84%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
VRCA 0.69 +0.02(2.65%)
Will VRCA be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRCA
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
Other News for VRCA
Needham Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals provides update on new commerical strategy for YCANTH
Verrica Pharmaceuticals provides update on new commerical strategy for YCANTH
PERCEPTIVE ADVISORS LLC Increases Stake in Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Appoints New Chief Operating Officer